New approaches of B-cell-directed therapy: beyond rituximab
- PMID: 18388516
- DOI: 10.1097/BOR.0b013e3282f5e08d
New approaches of B-cell-directed therapy: beyond rituximab
Abstract
Purpose of review: This study reviews therapeutic approaches of direct and indirect B-cell targeting in autoimmune diseases and their impact on protective immunity.
Recent findings: Beyond recent clinical experiences with rituximab as B-cell-depleting agent, other biologicals targeting CD20, such as ocrelizumab, ofatumumab, hA20, and TRU-015 mainly deplete B cells and are under clinical investigation in different entities. Moreover, anti-CD22 targeting as another approach that has been studied in clinical trials showed a modest depletion, but inhibition of B-cell activation. More indirect innovative B-cell-affecting therapies comprise blockade of cytokines, such as B-cell-activating factor (BAFF/BLyS), APRIL, and their receptors as well as blockade of costimulation. Although decreases of immunoglobulin levels were seen, so far no major increases in infections were reported.
Summary: The value of certain B-cell-depletion therapies as well as other therapies modulating B-cell functions needs to be further delineated, especially in the therapeutic regimen of rheumatoid arthritis, specific collagen vascular diseases and vasculitis. Long-term observations of protective immunity are also needed to further evaluate the rate of infections.
Similar articles
-
B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.J Allergy Clin Immunol. 2008 Jan;121(1):13-21; quiz 22-3. doi: 10.1016/j.jaci.2007.11.030. J Allergy Clin Immunol. 2008. PMID: 18206502 Review.
-
B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.J Rheumatol. 2008 Jul;35(7):1245-55. J Rheumatol. 2008. PMID: 18609733 Review.
-
Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.Pharmacol Ther. 2010 Mar;125(3):464-75. doi: 10.1016/j.pharmthera.2010.01.001. Epub 2010 Jan 25. Pharmacol Ther. 2010. PMID: 20097226 Review.
-
Emerging therapeutics for rheumatoid arthritis.Bull NYU Hosp Jt Dis. 2008;66(3):210-5. Bull NYU Hosp Jt Dis. 2008. PMID: 18937634 Review.
-
New treatments for SLE: cell-depleting and anti-cytokine therapies.Best Pract Res Clin Rheumatol. 2005 Oct;19(5):859-78. doi: 10.1016/j.berh.2005.05.006. Best Pract Res Clin Rheumatol. 2005. PMID: 16150407 Review.
Cited by
-
Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.Int J Mol Sci. 2020 Jul 16;21(14):5021. doi: 10.3390/ijms21145021. Int J Mol Sci. 2020. PMID: 32708663 Free PMC article. Review.
-
B-cell-directed therapies for autoimmune disease.Nat Rev Rheumatol. 2009 Aug;5(8):433-41. doi: 10.1038/nrrheum.2009.141. Epub 2009 Jul 7. Nat Rev Rheumatol. 2009. PMID: 19581902 Review.
-
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.Clin Exp Immunol. 2009 Aug;157(2):181-90. doi: 10.1111/j.1365-2249.2009.03977.x. Clin Exp Immunol. 2009. PMID: 19604257 Free PMC article. Review.
-
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.Ther Adv Neurol Disord. 2016 Jan;9(1):44-52. doi: 10.1177/1756285615601933. Ther Adv Neurol Disord. 2016. PMID: 26788130 Free PMC article. Review.
-
[Biological therapy for the treatment of rheumatic diseases].Internist (Berl). 2008 Aug;49(8):938-46. doi: 10.1007/s00108-008-2059-2. Internist (Berl). 2008. PMID: 18587545 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
